<DOC>
	<DOCNO>NCT02231762</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability combination Lanreotide Autogel 120 mg Temozolomide patient progressive gastro-entero-pancreatic neuroendocrine tumour ( GEP-NET ) grade G1 G2 ( G1/G2 ) . All progressive tumour classify accord Response Evaluation Criteria In Solid Tumours ( RECIST , 1.1 ) .</brief_summary>
	<brief_title>Combination Lanreotide Autogel 120mg Temozolomide Progressive GEP-NET</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Provision write informed consent prior study related procedure Inoperable , GastroEnteroPancreaticNeuroendocrine Tumour G1 G2 ( Proliferation Index , Ki67Index : 0 ≤20 % ) confirm pathological/histological assessment Progressive disease within 12 month inclusion ( RECIST 1.1 : increase &gt; 20 % tumour load ; Computer Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) Measurable disease accord RECIST 1.1 . Metastatic disease confirm CT/MRI . Functioning nonfunctioning NET ( G1 , G2 ) . Positive OctreoScan ( ≥ Grade 2 Krenning scale ) positive DOTA ( 1,4,7,10tetraazacyclododecane1,4,7,10tetraacetic acid ) TATE ( Tyr3Thre8Octreotide DOTATyr3octreotate ) /TOC ( Tyr3octreotide ) PET ( PositronEmissionTomography ) CT within 12 month prior screen Has diagnosis Insulinoma Has diagnosis multiple endocrine neoplasia ( MEN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>